Analysts Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $17.33

Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Get Free Report) have been given an average rating of "Buy" by the six analysts that are currently covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $17.33.

Several research analysts have commented on the stock. HC Wainwright restated a "buy" rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. Canaccord Genuity Group restated a "buy" rating and issued a $16.00 price objective on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reiterated a "buy" rating and issued a $18.00 price target on shares of Tenaya Therapeutics in a research note on Wednesday, December 18th. Piper Sandler reiterated an "overweight" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Leerink Partners reiterated an "outperform" rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th.

Tenaya Therapeutics Stock Performance

NASDAQ:TNYA traded up $0.04 during midday trading on Monday, reaching $1.50. 2,317,154 shares of the stock traded hands, compared to its average volume of 2,509,833. The company has a fifty day moving average of $2.31 and a 200 day moving average of $2.48. Tenaya Therapeutics has a 12 month low of $0.99 and a 12 month high of $7.01. The stock has a market capitalization of $118.83 million, a P/E ratio of -1.04 and a beta of 2.89.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.07. On average, analysts predict that Tenaya Therapeutics will post -1.35 EPS for the current fiscal year.

Institutional Trading of Tenaya Therapeutics

Several institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its position in Tenaya Therapeutics by 43.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company's stock valued at $72,000 after purchasing an additional 7,000 shares during the last quarter. Rhumbline Advisers grew its position in Tenaya Therapeutics by 10.5% during the 2nd quarter. Rhumbline Advisers now owns 78,160 shares of the company's stock valued at $242,000 after purchasing an additional 7,441 shares during the last quarter. State Street Corp grew its position in Tenaya Therapeutics by 0.9% during the 3rd quarter. State Street Corp now owns 1,058,898 shares of the company's stock valued at $2,044,000 after purchasing an additional 9,506 shares during the last quarter. Synovus Financial Corp purchased a new stake in Tenaya Therapeutics during the 3rd quarter valued at about $28,000. Finally, XTX Topco Ltd grew its position in Tenaya Therapeutics by 51.2% during the 3rd quarter. XTX Topco Ltd now owns 49,290 shares of the company's stock valued at $95,000 after purchasing an additional 16,687 shares during the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.